| Literature DB >> 32478050 |
Zeinab Nouri1, Marziyeh Hajialyani2, Zhila Izadi2, Roodabeh Bahramsoltani3,4, Mohammad Hosein Farzaei2,5, Mohammad Abdollahi6,7.
Abstract
Metabolic syndrome includes a series of metabolic abnormalities that leads to diabetes mellitus and cardiovascular diseases. Plant extracts, due to their unique advantages like anti-inflammatory, antioxidant, and insulin sensitizing properties, are interesting therapeutic options to manage MetS; however, the poor solubility and low bioavailability of lipophilic bioactive components in the herbal extracts are two critical challenges. Nano-scale delivery systems are suitable to improve delivery of herbal extracts. This review, for the first time, focuses on nanoformulations of herbal extracts in MetS and related complications. Included studies showed that several forms of nano drug delivery systems such as nanoemulsions, solid lipid nanoparticles, nanobiocomposites, and green-synthesized silver, gold, and zinc oxide nanoparticles have been developed using herbal extracts. It was shown that the method of preparation and related parameters such as temperature and type of polymer are important factors affecting physicochemical stability and therapeutic activity of the final product. Many of these formulations could successfully decrease the lipid profile, inflammation, oxidative damage, and insulin resistance in in vitro and in vivo models of MetS-related complications. Further studies are still needed to confirm the safety and efficacy of these novel herbal formulations for clinical application.Entities:
Keywords: diabetes; medicinal plants; metabolic syndrome; nanoparticles; nanophytomedicines; phytotherapy
Year: 2020 PMID: 32478050 PMCID: PMC7240035 DOI: 10.3389/fbioe.2020.00425
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1The pathophysiological mechanism of MetS. TNFα, tumor necrosis factor; PAI-1, plasminogen activator inhibitor-1; IL-6, interleukin 6; FFA, free fatty acid; PG, prostaglandin; TAG, triacylglycerol; LDL-C, low density lipoprotein; TC, total cholesterol; ROS, reactive oxygen species.
FIGURE 2The main mechanisms of medicinal plants for managing MetS. Nrf2, nuclear factor erythroid 2–related factor 2; GLUT4, glucose transporter type 4; TNFα, tumor necrosis factor; PAI-1, plasminogen activator inhibitor-1; IL-6, Interleukin 6; MDA, malondialdehyde; NF-κB, nuclear factor-κB; iNOS, inducible nitric oxide synthase.
FIGURE 3The role of extract-loaded nano-delivery systems in management of metabolic syndrome and its complications. STZ, streptozotocin; MCT, monocrotaline; PAH, pulmonary arterial hypertension; TC, total cholesterol; TAG, triacylglycerol; LDL-C, low-density lipoprotein-cholestrol; VLDL, very-low-density lipoprotein; HDL-C, high-density lipoprotein; SH, sulfhydryl group; GPx, glutathione peroxidase; SOD, superoxide dismutase; Nrf2, nuclear factor erythroid 2–related factor 2; RV, right ventricular; IL-6, interleukin 6; PDGF, platelet-derived growth factor; FGF, fibroblast growth factors; VEGF, vascular endothelial growth factor; TGFβ, transforming growth factor β; TNFα, tumor necrosis factor; GLUT4, glucose transporter type 4; HbA1c, hemoglobin A1c; PLGA poly lactic-co-glycolic acid.
Herbal extracts based nanoscale drug delivery systems for treating metabolic syndrome.
| Plant | Nanoformulation Type | Disorder | Cellular/Animal model | Size | Outcome | References |
| Nanostructured lipid carrier | Diabetes mellitus | 220 nm | ↑insulin sensitivity ↑Glucose uptake | |||
| Solid lipid nanoparticles | STZ + HFD-induced diabetes mellitus | 22–70 nm | ↓insulin resistance ↑CAT↑SOD ↑GSH | |||
| Green synthesized Ag nanoparticle | STZ-induced Diabetes mellitus | – | ↓blood glucose ↑serum insulin ↓ alpha amylase ↑glucose uptake | |||
| chitosan nanoparticles | STZ-induced diabetes mellitus | 50.42–73.34 nm | ↓FBS ↓HbA1c ↑SOD ↑ CAT ↑GSH | |||
| PLGA nano-encapsulated | Arsenic- induced diabetes mellitus | 122 nm | ↑ glucose uptake ↑glucokinase ↑GLUT4 ↓ blood glucose, ↓NF-κB ↓ iNOS | |||
| Green synthesized Ag nanoparticle | Glucose- stressed cells | 40–100 nm | ↓cell size ↓lipid peroxidation | |||
| Green synthesized Ag nanoparticle | Glucose- induced diabetes mellitus | 5–21 nm | ↓blood glucose ↓insulin secretion ↓TC | |||
| Green synthesized Ag nanoparticle | STZ-induced diabetes mellitus | 30–60 nm | ↓blood glucose ↓HbA1c ↑insulin ↑glycogen | |||
| Green synthesized Au nanoparticle | STZ-induced diabetes mellitus | 55.2–98.4 nm | ↓Blood glucose ↓HbA1c ↓ LDL-C ↑ HDL-C | |||
| Green synthesized Au nanoparticle | ALX–induced diabetes mellitus | Ave:50 nm | ↓ TNFα↓IL6 ↓CRP ↓HbA1c ↓ LDL-C ↑HDL-C | |||
| Green synthesized Au nanoparticle | STZ-induced diabetes mellitus | 4–23 nm | ↓ blood glucose ↓MDA ↓ COX2 | |||
| Green synthesized Au nanoparticle | Diabetes mellitus | 17–40 nm | ↑ glucose utilization | |||
| Green synthesized Au nanoparticle | STZ –induced diabetes mellitus | Ave: 50 nm | ↓Blood glucose ↑body weight ↓super oxide anion ↓lipid peroxidation | |||
| TiO2 nanomaterial | ALX-induced diabetes mellitus | Ave: 4 nm | ↓blood glucose ↑insulin ↓HbA1c ↓TC ↓TAG | |||
| Green synthesized ZnO nanoparticle | Diabetes mellitus | Ave: 27.61 | ↓α-amylase ↓α-glucosidase. | |||
| Green synthesized ZnO nanoparticle | Diabetes mellitus | Ave: 25.66 | ↓α-amylase ↓α-glucosidase. | |||
| Green synthesized ZnO nanoparticle | STZ-induced diabetes mellitus | 12-46 nm | ↓TNF-a ↓IL-1b ↓IL-6 ↑ IL-4 ↑ IL-10 ↑GK ↑IRA ↑GLUT2 ↓ PKLR | |||
| Green synthesized ZnO nanoparticle | ALX-induced diabetes mellitus | Ave: 13.9 nm | ↓ blood sugar ↑HDL-C ↓TC | |||
| Nanophytosome | HFD-induced obesity | 51.66–667.24 nm | ↓ body weight, ↓TC, LDL-C | |||
| Nanoemulsion | HFD-induced dyslipidemia | 20–46 nm | ↓TC ↑ HDL-C ↓AST ↓ALT | |||
| Nanoemulsion | HCD-induced dyslipidemia | 133.4 nm | ↓TC ↓ LDL-C ↑GSH ↓fat droplet in liver | |||
| Nanoencapsulated | MCT-induced Pulmonary arterial hypertension | 139.03 nm | ↑SH ↑Gpx ↑SOD ↑Nfr2 ↓RV hypertrophy | |||
| Nanobiocomposite (cellulose nanocrystals and AgNPs) | Diabetic wound | Nano crystal: 18 ± 0.5 nm and AgNPs 16 ± 3 nm | ↓TNFα↓IL6 ↑PDGF ↑FGF ↑VEGF ↑ TGFβ↑Density of collagen fibers | |||
| Nanobiocomposite (cellulose nanocrystals and AgNPs) | Diabetic wound | Nano crystal: 20 ± 1 nm and AgNPs: 22 ± 7 nm | ↓TNFα↓IL6 ↑PDGF ↑FGF ↑VEGF ↑ TGFβ↑Density of collagen fibers | |||
| Green synthesized Ag nanoparticle | Diabetes mellitus | 5–35 nm ave:15 nm | ↓α-amylase ↓α-glucosidase | |||
| Nanoemulsion | Diabetes mellitus | 102.2 nm | ↓α-amylase ↓α- glucosidase | |||
| PLGA nano-encapsulated | STZ –induced diabetes mellitus | – | ↓blood glucose, ↑insulin (I&II) and GLUT4 ↓GLUT2 | |||
| Solid lipid nanoparticle | STZ and fructose induced –diabetes mellitus | Ave: 200 nm | ↓ blood glucose ↑insulin level | |||
| Nanoemulsion | ALX-induced diabetes mellitus | <100 nm | ↑SOD, ↑GPx, ↓MDA | |||
| Green synthesized AgNPs | STZ –induced diabetes mellitus | 123.8 nm | ↓ blood sugar | |||
| Green synthesized ZnO nanoparticle | ALX-induced diabetes mellitus | 18.8–19.9 nm | ↓FBS, TC, TAG ↑insulin, HDL-C | |||
| Green synthesized ZnO nanoparticle | ALX-induced diabetes mellitus | 14 nm | ↓FBS, TC, TAG ↑insulin, HDL-C | |||
| Green synthesized Au nanoparticle | STZ-induced diabetic nephropathy | 20 nm | ↓MAPK/NF-κB/STAT3 ↓ RAGE- NOX-4/p47phox ↓ROS ↑Nrf2 ↓renal fibrosis | |||
| Green synthesized Ag nanoparticle | Diabetic rats intoxicated with Aluminum | 35 nm | ↓deterioration in retinal cell layer ↓ Aluminum and glucose | |||
| Green synthesized Au nanoparticle | HFD and STZ- induced obese diabetes rats | 21 nm | ↓TNFα and IL-β ↓leptin ↑adiponectin ↓body weight and blood glucose |